Skip to main content

Table 2 Henoch-Schönlein Purpura events. (N = 1002)

From: Incidence and risk factors for recurrent Henoch-Schönlein purpura in children from a 16-year nationwide database

 

Only one Episode (n = 838), n (%)

Recurrent Episode (n = 164), n (%)

Crude HR (95% CI)b

p value

Sex

 Male

412 (49.2)

91 (55.5)

1.27(0.93–1.73)

0.131

 Female

426 (50.8)

73 (44.5)

1.00

 

Age, y

 Mean ± SD

6.85 ± 3.70

7.22 ± 3.37

1.03 (0.99–1.07)

0.224

  0–6

499 (59.5)

82 (50.0)

1.00

 

  7–12

268 (32.0)

71 (43.3)

1.55 (1.13–2.13)

0.007

  13–18

71 (8.5)

11 (6.7)

0.95 (0.51–1.79)

0.880

Economics Status

 Normal

771 (92.0)

154 (93.9)

1.00

 

 Low income

67 (8.0)

10 (6.1)

0.77 (0.40–1.45)

0.411

Comorbidities

 Asthma

356 (42.5)

68 (41.5)

0.97 (0.71–1.33)

0.866

 Allergic rhinitis

627 (74.8)

139 (84.8)

1.80 (1.18–2.77)

0.006

 Atopic dermatitis

221 (26.4)

47 (28.7)

1.13 (0.80–1.58)

0.484

Clinical course

 GI symptoms

799 (95.3)

161 (98.2)

2.50 (0.80–7.82)

0.116

 Renal symptoms

57 (6.8)

36 (22.0)

3.15 (2.17–4.56)

< 0.001

 Joint Pain

111 (13.2)

30 (18.3)

1.39 (0.94–2.07)

0.102

Initiation of Steroid(1st)

 No steroid use

496 (59.2)

67 (40.9)

1.00

 

 Early (<  14 days)

19 (2.3)

4 (2.4)

1.50 (0.55–4.12)

0.430

 Late (≥  14 days)

323 (38.5)

93 (56.7)

1.97 (1.44–2.70)

< 0.001

Duration of Steroid

No steroid use

496 (59.2)

67 (40.9)

1.00

 

 SG (<  10 days)

284 (33.9)

48 (29.3)

1.20 (0.83–1.74)

0.329

 LG(≥  10 days)

58 (6.9)

49 (29.9)

4.98 (3.45–7.21)

< 0.001

  1. Abbreviations: HSP Henoch-Schönlein Purpura, SD standard deviation, SG short-term group, LG long-term group, HR Hazard ratio
  2. Cox proportional Regression Analysis
  3. bHazard ratio of 1.00 indicates reference group